🚀 Exciting announcement! ⭐️ Join us at #BAUS25 for our special session on Monday, 16 June! 🕓 16:30 - 16:45 📍 Charter 3 📢 We are thrilled to welcome our keynote speaker, Freddie Hamdy, who will discuss, "The Challenge of Misinformation"! #BURSTatBAUS #UroSoMe @bausurology.bsky.social

An important (very short) film from Steve McQueen - don’t be embarrassed to talk about #ProstateCancer. Can effect all men but there’s a higher risk for black men. www.embarrassedfilm.org It’ll take less than 2 mins of your time to watch. An inspiring talk at #BAUS25

Inaccuracy of rapid at home PSA tests www.bbc.co.uk/news/article...

Woohoo! Great work team @jimcatto.bsky.social bmjopen.bmj.com/content/bmjo...

🏃 Flying start to #IP9ATLAS - first 5️⃣0️⃣ patients recruited! 🔎 Comparing regular MRI scans to standard of care in patients with prostate cancer on active surveillance 🎉 Thank you to our site teams Imperial College Healthcare NHST, Dartford and Gravesham NHST & Frimley Health NHSFT

Can mpMRI replace TURBT for faster treatment in MIBC? A randomized study shows that the mpMRI-first approach reduced the time to treatment by 45 days (53 vs. 98 days). No harm to non-MIBC patients. A game-changer for staging? #Oncology @oncoalert.bsky.social ascopubs.org/doi/10.1200/JC…

Great to see this finally out #bladdercancer ascopubs.org/doi/10.1200/...

Now published: This MA is the basis for our ongoing #ZMoveMent1 study evaluating the impact of endurance*resistance training on QoL, oncological outcomes, fitness in #ProstateCancee pts 👉 we still don’t use #PhysicalExercise in cancer pts in an optimal way 👉 www.mdpi.com/2072-6694/16...

Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer oncodaily.com/insight/sasa... #BladderCancer #Cancer #EventFreeSurvival #EFS #OncoDaily #Oncology #Pfizer #Sasanlimab

#CREST trial with positive results for #PD-1 in HR #NMIBC! ✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC. ✅The study met its primary endpoint with significant improvement of EFS pfizer.com/news/press-rel… @oncodaily.bsky.social

Key findings include an increase in men newly diagnosed with prostate cancer: in 2023 in England, a 9% increase when compared to 2022 and a 25% increase compared to 2019. In 2022 in Wales, a 26% increase compared to 2021.

Geographic patterns of #prostatecancer reflect awareness, mens health and PSA testing. Big differences exist in the UK and other countries @prostatecanceruk.bsky.social prostatecanceruk.org/about-us/new...

Credit the authors ... its hard to find defendants of TRUS-Bx in an era of TREXIT. RCTs mostly show equivalence but fewer infections - see www.bmj.com/content/387/... There is loss of equipoise amongst urologists. Patient views under-represented. www.eu-focus.europeanurology.com/article/S240...

(Over)diagnosis of very low risk #prostatecancer in the USA. The disease that won't go away ..... despite MRI use. Time to abandon random biopsy @dr-coops.bsky.social euoncology.europeanurology.com/article/S258...

Nice. How to write a Response to reviewers. Amazing how many authors ignore simple questions. Reviewers are usually helping you improve your work. Well done @vickersbiostats.bsky.social @euplatinum.bsky.social www.europeanurology.com/article/S030...

1. HIFU vs Radical prostatectomy non-randomised comparison. Large 1,967 HIFU & 1,361 RP, contemporary 2015-19. 62% intermediate-risk PC. Similar adverse events except long term continence and erectile scores. Less salvage treatments with HIFU. www.europeanurology.com/article/S030...

I’ve just signed the @prostatecanceruk.bsky.social letter to the Secretary of State for Health and Social Care @rthonwesstreeting.bsky.social asking for simple and free changes to outdated #prostatecancer testing guidelines. Add your name now - it takes less than a minute!

Moving from the dance floor 🕺💃 to the balcony 🏛️” - Great leadership requires both action & reflection. Insightful session by @brookmans76.bsky.social at #EAUTalentIncubator on finding balance in leadership! 👏✨ @uroweb.bsky.social #LeadershipDevelopment

The National Prostate Cancer Audit State of the Nation Report 2024 has been published! It is available here www.npca.org.uk/reports/npca... alongside its appendix, methodology supplement and data tables.

In over 460,000 women throughout Germany, #AI second readings of mammograms led to improved breast cancer detection, a lower recall rate, and significantly reduced workload nature.com/articles/s41... open-access

Mosaic pattern loss of Y chromosome, which occurs in ~40% of men by age 70, is causally linked to heightened risk of many diseases, including cardiovascular, bladder cancer, and Alzheimer's. But it's almost never assessed clinically. A new review nature.com/articles/s41...

Bonus effect. When a drug for diabetes significantly reduces kidney stones, results of a randomized trial of empagliflozin (Jardiance), a SGLT-2 inhibitor, in people without diabetes www.nature.com/articles/s41...

“The drug is life-changing. To come out the other side with this extra treatment, it makes it easier to be hopeful and confident of being healthy.” Annie Baker was treated for #BreastCancer with olaparib – a drug developed following crucial involvement by ICR scientists.

Grateful every day to lead the incredible Fox Chase Urology team as we tackle the region’s toughest cases and push the boundaries of our field (like this week’s JCO pub: pubmed.ncbi.nlm.nih.gov/39680823/). Happy and healthy holiday season to all! www.foxchase.org/clinical-car...

Initial active surveillance and watchful waiting significantly increased for intermediate–risk prostate cancer between 2010 and 2020. https://ja.ma/4042hPZ

Congratulations #IP7PACIFIC - 8️⃣6️⃣5️⃣ patients recruited so far! ⏱️ Evaluating the role of biparametric MRI & image-fusion targeted biopsies to detect prostate cancer 🔗 imperial.ac.uk/news/233114/... 🎉 Thank you to all of our outstanding recruitment sites!

Genomic sequencing identified hereditary cancer risks in 9% of patients after uninformative gene panels. However, most findings lacked evidence-based guidelines. #Genomics #Cancer #Oncology @oncoalert.bsky.social @viveksubbiah.bsky.social @realbowtiedoc.bsky.social doi.org/10.1200/PO-2...

Can some MIBC patients safely skip cystectomy? In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%. @oncoalert.bsky.social @oncbrothers.bsky.social @erplimackmd.bsky.social doi.org/10.1200/JCO-...

(RETAIN 1) Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive #BladderCancer 1ry endpoint NOT met, 48% of patients in the AS group remained metastasis-free with intact bladders, show that biomarker-driven selection could spare some from cystectomy https://buff.ly/41DG1h2

At @science.org, the Breakthrough of the Year 2024 Lenacapavir – a new injectable drug that prevents HIV infection "The Long Shot" science.org/doi/10.1126/...

🚀 Early-Bird Registration for the Imperial Prostate & Focal Therapy Society Masterclass 2025 is open! #ipftsmasterclass25 📍Friday 11 April - Saturday 12 April 2025 📍South Kensington, London UK 🎟️ imperialprostatemasterclass.org

77-year-old television announcer Tomoaki Ogura, who served as host of a popular morning show for 22 years, died of bladder cancer at his home in Tokyo on Monday.

Eddie Jordan had a message for people, after revealing a diagnosis for bladder and prostate cancer earlier this year. www.planetf1.com/news/eddie-j...

Former F1 team boss Eddie Jordan has revealed that he is battling an "aggressive" form of cancer, which was diagnosed earlier this year and spread from his prostrate and bladder to spine and pelvis. And he had an important message to share:

Eddie Jordan has revealed that he is battling cancer, prostate and bladder cancer that has spread to his pelvis and spine, with the spread being labelled “aggressive”. #F1

Huge thanks to everyone who’s chipped in to make LBD interventions happen this year. We’re 100% funded by small donations & refuse big donors to protect us from becoming reliant on any individual source. Wanna help? Link in bio👆

Also sharing the link to donation in memory and honor of Dr. Felix Feng here: ow.ly/Uc3H50TSBiC

Kicked off our 3rd and final day with the YUO program and a fantastic lecture by Dr. Christopher Kane. Congratulations to Dr. Kane on being the Joseph A Smith Jr Mentorship award recipient #SUO24

Impressive results: Ph 2 trial: BCG + gemcitabine in BCG-exposed #NMIBC (HG Ta/T1/CIS) ✅ 6 & 12 mo CR: 94% & 81% ✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76% ✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social

If there is only one thing you will read today - make it this one! So many lessons on how to care: -illuminate the personhood -understand life outside the hospital -practical compassion -sit with darkness tinyurl.com/4h2u476m

Rich Matulewicz #SUO24 “Blockbuster New Therapy for Cancer…. Smoking Cessation “. @joshmeeks.bsky.social @yawnyame.bsky.social @wandering-gu.bsky.social

A new paper from our TOPARP trial 'Elucidating acquired PARP inhibitor resistance in advanced prostate cancer' has been published in Cancer Cell. This is the third translational paper using data and samples collected in the TOPARP trial. #MedSky #ProstateCancer www.sciencedirect.com/science/arti...

Our first Editor's Choice Article has been chosen by our EiC Alberto Briganti: EAU Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update by Paolo Gontero et al Read the full article here: buff.ly/3AXFEDi #UroSky

Our EiC's @gratzke.bsky.social Editor's Choice of the Week: The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and MRI-targeted Biopsies are Discordant by Simone Scuderi et al Read the full article here: buff.ly/4fS0sv9 #UroSky #EditorsChoice

What were the most inspiring 2024 discoveries in cancer? Cancer Discovery asked me, Katherine Aird, Aadel Chaudhuri, Jennifer Guerriero, Shiri Gur-Cohen, Benjamin Izar, Brittany Jenkins, Delphine Merino, Alejo Rodriguez-Fraticelli & Shensi Shen, & here's what we said aacrjournals.org/cancerdiscov...